To the Editor:

Despite the fact that pulmonary rehabilitation (PR) is the most powerful nonpharmacological intervention to improve the symptoms, exercise capacity and quality of life of people living with chronic lung disease \[[@C1]\], fewer than 2% of eligible patients enrol \[[@C2], [@C3]\]. While preparing a joint American Thoracic Society (ATS)/European Respiratory Society (ERS) Policy Statement on pulmonary rehabilitation \[[@C4]\], we developed a survey to better understand patients\' perspectives on PR, and to identify challenges faced both by patients who have taken part in PR and those who might be eligible but have not had the opportunity. The survey was disseminated *via* the European Lung Foundation/ERS and ATS Public Advisory Roundtable professional patient networks, and *via* the COPD Foundation and Pulmonary Fibrosis Foundation to patients with a wide range of chronic lung diseases. The survey was available online from July, 2014 to November, 2014 in 10 languages (Dutch, English, Flemish, French, German, Greek, Italian, Polish, Portuguese and Spanish). Responses were received from 1685 people (73% female) with self-reported chronic lung disease in 29 countries (USA: 71.1%; Europe: 27.4%; others: 1.5%) and were included in the analyses ([table 1](#TB1){ref-type="table"}). TABLE 1Patient survey on experiences relating to pulmonary rehabilitation (PR)**Total number of respondents n**1685**What is your age group?** 18--30 years24 (1.4) 31--50 years287 (17.0) 51--60 years452 (26.8) 61--70 years520 (31.4) \>70 years393 (23.3) Not reported9 (0.1)**Gender** Women1229 (72.9) Men450 (26.7) Not reported6 (0.4)**Have you ever been told about PR by your healthcare provider?** Yes1009 (59.9) No614 (36.4) Not sure62 (3.7)**Has a healthcare provider ever discussed the benefits of PR with you?** Yes939 (55.7) No702 (41.7) Not sure41 (2.4) Not reported3 (0.2)**Have you ever taken part in PR?** Yes904 (53.6) No770 (45.7) Not sure10 (0.6) Not reported1 (0.1)**If you have taken part in PR, how did you hear about it? You can choose more than one option.** Healthcare provider807 (89.3) On the internet74 (8.2) Published literature, such as newspapers or academic journals46 (5.1) Pamphlet/flyer30 (3.3) Advertisement (on TV, radio or in a magazine)5 (0.6) A friend or a family member69 (7.6) Someone who had taken part in PR109 (12.1)**If you have taken part in PR, did you....?** Complete the whole programme777 (86.0) Stop early98 (10.8) Not reported29 (3.2) Reasons for stopping early (if applicable) (individual patient responses below):  Medical comorbidities/accident  Costs of the PR programme  Exacerbation of chronic lung disease  Death in the family  Still actively participating in the PR programme**If you have participated in PR, what is the lung condition for which you were referred?** COPD495 (54.8) Pulmonary fibrosis (or interstitial lung disease)201 (22.2) Pulmonary hypertension56 (6.2) Asthma41 (4.5) Cystic fibrosis12 (1.3) Bronchiectasis15 (1.7) Lung cancer14 (1.6) Other (including but not limited to) (individual patient responses below):70 (7.7)  After pneumonia  α~1~-antitrypsin deficiency  Chronic bronchitis  After lung transplantation**Do you think that PR should be a part of healthcare services available to all patients that might benefit from it?** Yes1549 (91.9) No3 (0.2) Not sure111 (6.6) Not reported22 (1.3)**Have you experienced any challenges to taking part in PR? (Multiple answers possible.)** No challenges670 (39.8) Never heard of PR377 (22.4) Not enough information to decide whether I want to participate162 (9.6) Not sure whether it would help me150 (8.9) Worried it might be painful37 (2.2) There is no PR service in my area134 (8.0) The doctor did not think it would help me44 (2.6) Did not qualify for the service in my area38 (2.3) Cannot get to the appointments, because the service is too far away52 (3.1) Not covered by my insurance93 (5.5) Lack of encouragement from the people running the program/staff45 (2.7) Family not supportive19 (1.1) Low self-confidence or anxiety72 (4.3) Other (including, but not limited to) (individual patient responses below):247 (14.7)  Medical comorbidities  Disease instability/frequent exacerbations  Inconvenient PR times (still working/need for childcare)  PR programme (initially) limited to COPD patients only  Poor/no PR facilities available  Exercising with people on oxygen supplements was detrimental  No/pending approval from insurance  Lack of clarity in the referral process and reimbursement  (Co-)pay is too expensive  Transportation problems  Patient believes to be too ill to participate in PR  Patients believes to be active enough/PR not necessary  Physician unknown with the effects of PR**If you have participated in PR, what do you feel were the major benefits of the programme for you? You can choose more than one option.** Improved physical functioning in daily life658 (75.8) Improved mood or sense of emotional wellbeing439 (48.6) Improved knowledge about lung condition474 (52.4) Improved control of symptoms416 (46.0) Improved social functioning261 (28.9) Other (including but not limited to) (individual patient responses below):277 (30.6)  A combination of the abovementioned improvements  Improved quality of life  Improved mobility  Empowering  Improved lifestyle  Improved self-confidence  Improved understanding of my problems  No change/improvementData are presented as n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease.

A majority of patients were 61 years of age or older (54.7%). 92% of respondents thought that PR should be a part of healthcare services available to all patients that might benefit, yet 46% of respondents had never taken part in a PR programme. 60% reported having experienced challenges to taking part in PR ([table 1](#TB1){ref-type="table"}). Approximately two-fifths of respondents reported that their healthcare provider had never told them about PR, or the benefits of PR for people living with chronic lung disease. 18% felt they did not have enough information to decide about participating or were not sure it would help them. Nearly one-fifth of respondents faced logistical challenges, such as no PR service available or lack of insurance coverage. Emotional challenges were also an obstacle to participation.

Of the respondents who had participated in PR, most had heard about it through their healthcare provider ([table 1](#TB1){ref-type="table"}). A majority of these individuals reported improvements in physical functioning in daily life, mood or sense of emotional wellbeing, knowledge about their lung condition, control of symptoms, social functioning, or a combination thereof ([table 1](#TB1){ref-type="table"}). PR participants were asked to respond to the question "What would you say to someone considering attending a PR session for the first time?". Representative responses included: "Absolutely do it!", "A must!", "It allows you to move around and breathe better", "Absolutely go all in!", "Be open about your symptoms and condition", "Begin as soon as possible", "Best thing I ever did to help manage this disease", "Don\'t be a damn fool -- go and help yourself", "Don\'t be scared", "It will change your life", and "It works!". None of the respondents made negative comments or recommended against participation in PR. Patients who had participated also offered suggestions as to how to improve the PR experience. Representative suggestions included having PR facilities closer to home, having appropriate funding and lower "out of pocket" costs, a longer duration of PR programme or the opportunity to do two PR programmes per year, opportunity to transition to a maintenance programme, having the option for PR sessions during evenings or the weekend days, addition of yoga and/or meditation to the PR programme, and the importance of individualisation of the PR programme to each patient\'s condition (including the educational component and need for staff to have knowledge of respiratory disorders other than chronic obstructive pulmonary disease (COPD)). Notably, three-fifths of respondents reported that they experienced one or more challenges to taking part in PR.

In 2015, the official ATS/ERS policy statement on enhancing implementation, use and delivery of pulmonary rehabilitation highlighted the need to increase patients\' and healthcare providers\' awareness and knowledge of PR, as well as to increase patients\' access to PR \[[@C4]\]. For example, it was recommended that professional societies and patient advocacy and education experts develop education materials for people living with chronic respiratory disease regarding the process and benefits of PR. Public awareness campaigns are also needed. The current survey data confirms the need for greater healthcare professionals\' knowledge and awareness of PR to foster patient referrals, and for new PR services to reduce travel distance and transportation problems, for increased insurance coverage for PR, and expanded PR services that do not focus solely on COPD.

Our survey-based study has some limitations. Given that the majority of respondents were from Europe and North America, the generalisability of our findings to other first world and/or developing countries is unknown. Moreover, the participation and engagement of many of our respondents in patient networks and health societies might have introduced bias into the survey findings, since these individuals may have been especially motivated to take control of and manage their respiratory disease. Future efforts to learn more about the perspectives of individuals from other countries underrepresented in the present survey, and those not engaged in patient networks or health societies would be both informative and beneficial.

In keeping with the ATS/ERS policy statement on PR \[[@C4]\], however, this survey demonstrates clearly that people with chronic lung diseases in Europe and the USA want to learn about and be able to participate in PR, yet are often unaware of it, its benefits or lack access to it. Importantly, these findings are probably "the tip of the iceberg", since only people with computer and internet access could respond to this survey. Referrals, access to and uptake of PR are likely significantly further diminished among those from more remote, under-served or poverty-stricken areas \[[@C5]\]. We believe this is an important healthcare disparity that should be addressed by healthcare providers and health systems in the years to come.
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